Literature DB >> 22050460

Clinical and neurophysiologic features of progressive myoclonus epilepsy without renal failure caused by SCARB2 mutations.

Guido Rubboli1, Silvana Franceschetti, Samuel F Berkovic, Laura Canafoglia, Antonio Gambardella, Leanne M Dibbens, Patrizia Riguzzi, Claudio Campieri, Adriana Magaudda, Carlo Alberto Tassinari, Roberto Michelucci.   

Abstract

PURPOSE: Mutations of the SCARB2 gene cause action myoclonus renal failure syndrome (AMRF), a rare condition that combines progressive myoclonus epilepsy (PME) with severe renal dysfunction. We describe the clinical and neurophysiologic features of PME associated with SCARB2 mutations without renal impairment.
METHODS: Clinical and neurophysiologic investigations, including wakefulness and sleep electroencephalography (EEG), polygraphic recording (with jerk-locked back-averaging and analysis of the EEG-EMG (electromyography) relationship by coherence spectra and phase calculation), multimodal evoked potentials, and electromyography were performed on five Italian patients with SCARB2 mutations. KEY
FINDINGS: The main clinical features were adolescent-young adulthood onset, progressive action myoclonus, ataxia, absence of cognitive deterioration and, in most cases, epilepsy. The severity of the epilepsy could vary from uncontrolled seizures and status epilepticus in patients with adolescent onset to absent or rare seizures in patients with adult onset. Relevant neurophysiologic findings were a pronounced photosensitivity and massive action myoclonus associated with rhythmic myoclonic jerks at a frequency of 12-20 Hz, clinically resembling a postural tremor. The cortical origin of rhythmic myoclonus was demonstrated mainly by coherence and phase analysis of EEG-EMG signals indicating a significant EEG-EMG coupling and a direct corticospinal transfer. SIGNIFICANCE: Our patients with SCARB2 mutations showed the clinical and neurophysiologic phenotype of PME, in which epilepsy could be extremely severe, extending the spectrum reported in the typical AMRF syndrome. Patients with PME of unknown origin of adolescent or young adult onset, with these neurophysiologic features, should be tested for SCARB2 mutations, even in the absence of renal impairment. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22050460     DOI: 10.1111/j.1528-1167.2011.03307.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  16 in total

Review 1.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

Review 2.  Genetics of epilepsy and relevance to current practice.

Authors:  Roberto Michelucci; Elena Pasini; Patrizia Riguzzi; Lilia Volpi; Emanuela Dazzo; Carlo Nobile
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

3.  Progressive myoclonic epilepsies: definitive and still undetermined causes.

Authors:  Silvana Franceschetti; Roberto Michelucci; Laura Canafoglia; Pasquale Striano; Antonio Gambardella; Adriana Magaudda; Paolo Tinuper; Angela La Neve; Edoardo Ferlazzo; Giuseppe Gobbi; Anna Teresa Giallonardo; Giuseppe Capovilla; Elisa Visani; Ferruccio Panzica; Giuliano Avanzini; Carlo Alberto Tassinari; Amedeo Bianchi; Federico Zara
Journal:  Neurology       Date:  2014-01-02       Impact factor: 9.910

4.  A compound heterozygous missense mutation and a large deletion in the KCTD7 gene presenting as an opsoclonus-myoclonus ataxia-like syndrome.

Authors:  Lubov Blumkin; Sara Kivity; Dorit Lev; Sarit Cohen; Ruth Shomrat; Tally Lerman-Sagie; Esther Leshinsky-Silver
Journal:  J Neurol       Date:  2012-05-26       Impact factor: 4.849

5.  A novel homozygous splice-site mutation in SCARB2 is associated with progressive myoclonic epilepsy with renal failure.

Authors:  Abolfazl Yari; Reza Molla Ali-Nejad; Nasrollah Saleh-Gohari
Journal:  Neurol Sci       Date:  2021-03-26       Impact factor: 3.307

Review 6.  Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection.

Authors:  Wolfgang Löscher; Charles L Howe
Journal:  Front Mol Neurosci       Date:  2022-05-09       Impact factor: 6.261

7.  Identification of COL6A2 mutations in progressive myoclonus epilepsy syndrome.

Authors:  Siamak Karkheiran; Catharine E Krebs; Vladimir Makarov; Yalda Nilipour; Benjamin Hubert; Hossein Darvish; Steven Frucht; Gholam Ali Shahidi; Joseph D Buxbaum; Coro Paisán-Ruiz
Journal:  Hum Genet       Date:  2012-11-09       Impact factor: 4.132

Review 8.  Myoclonus-Ataxia Syndromes: A Diagnostic Approach.

Authors:  Malco Rossi; Sterre van der Veen; Marcelo Merello; Marina A J Tijssen; Bart van de Warrenburg
Journal:  Mov Disord Clin Pract       Date:  2020-11-03

Review 9.  Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.

Authors:  Emily C Daykin; Emory Ryan; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2021-01-09       Impact factor: 4.797

Review 10.  Gaucher disease: Basic and translational science needs for more complete therapy and management.

Authors:  Gregory A Grabowski; Armand H M Antommaria; Edwin H Kolodny; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-12-29       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.